Patents Assigned to NICONOVUM USA, INC.
-
Patent number: 11547660Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.Type: GrantFiled: August 27, 2021Date of Patent: January 10, 2023Assignee: Niconovum USA, Inc.Inventors: Anders Axelsson, Arne Kristensen, Henri Hansson
-
Patent number: 10532046Abstract: The present disclosure relates to compositions that are useful in the delivery of various materials. In particular, the compositions comprise a suspension wherein an internal phase material is surrounded by an external phase material. The internal phase specifically can be a hydrophilic material, and the external phase specifically can be a hydrophobic material. The materials are combined so that the internal phase is substantially encapsulated by the external phase such that release can be controlled in relation to osmotic pressure differentials. The suspension can be combined with a carrier, and various systems and products can be formed with the suspension and optional carrier, such as oral strips, spray delivery systems, smokeless tobacco products, aerosol delivery devices, cigarettes, and packaging.Type: GrantFiled: December 3, 2015Date of Patent: January 14, 2020Assignee: Niconovum USA, Inc.Inventors: James William Rogers, Michael F. Davis, Percy D. Phillips, Karen V. Taluskie, Stephen Benson Sears, Ercilia Hernandez Garcia
-
Patent number: 10219999Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.Type: GrantFiled: November 30, 2012Date of Patent: March 5, 2019Assignee: Niconovum USA, Inc.Inventors: Anders Axelsson, Arne Kristensen, Henri Hansson
-
Patent number: 10092715Abstract: Disclosed is a method for oral administration of a liquid containing an active substance to a subject for improved absorption into the subject's bloodstream. It includes the steps of providing a delivery device containing the liquid and having a mouthpiece for directing the liquid in a defined direction during delivery; directing the mouthpiece toward a localized area of the subject's mouth being especially suitable for relatively increased uptake and relatively faster onset of action of the active substance; and delivering a measured amount of the liquid directly to the area using the device. Also disclosed is a spray device that includes a container capable of holding a liquid containing an active substance, and a mouthpiece constructed to dispense the liquid in a defined direction and directly to a localized area of a subject's mouth, the localized area being the oral vestibule.Type: GrantFiled: September 27, 2007Date of Patent: October 9, 2018Assignee: Niconovum USA, Inc.Inventors: Anders Axelsson, Karl Olov Fagerström
-
Patent number: 9937168Abstract: A composition intended to be employed for therapeutic purposes incorporates nicotine and at least one other nicotinic compound. Representative forms of nicotine can be as a free base (e.g., as a mixture of nicotine and microcrystalline cellulose), as a form of nicotine salt (e.g., as nicotine bitartrate) or as nicotine polacrilex. The other nicotinic compound is a compound that can be considered to bind selectively to certain nicotinic receptor subtypes, and particularly those of the central nervous system. For example, the other nicotinic compound can be a compound that binds selectively to the nicotinic receptor subtypes ?7 or ?4?2. The composition is useful for treatment of central nervous system conditions, diseases and disorders, and as a nicotine replacement therapy.Type: GrantFiled: June 8, 2017Date of Patent: April 10, 2018Assignee: Niconovum USA, Inc.Inventor: August J. Borschke
-
Patent number: 9907748Abstract: A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and/or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.Type: GrantFiled: October 21, 2011Date of Patent: March 6, 2018Assignee: Niconovum USA, Inc.Inventors: August Joseph Borschke, Darrell Holton, Jr.
-
Publication number: 20170326138Abstract: A composition intended to be employed for therapeutic purposes incorporates nicotine and at least one other nicotinic compound. Representative forms of nicotine can be as a free base (e.g., as a mixture of nicotine and microcrystalline cellulose), as a form of nicotine salt (e.g., as nicotine bitartrate) or as nicotine polacrilex. The other nicotinic compound is a compound that can be considered to bind selectively to certain nicotinic receptor subtypes, and particularly those of the central nervous system. For example, the other nicotinic compound can be a compound that binds selectively to the nicotinic receptor subtypes ?7 or ?4?2. The composition is useful for treatment of central nervous system conditions, diseases and disorders, and as a nicotine replacement therapy.Type: ApplicationFiled: June 8, 2017Publication date: November 16, 2017Applicant: NICONOVUM USA, INC.Inventor: August J. Borschke
-
Patent number: 9763928Abstract: The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the pharmaceutical composition. The invention further provides methods for making and using the pharmaceutical composition.Type: GrantFiled: February 10, 2012Date of Patent: September 19, 2017Assignee: Niconovum USA, Inc.Inventors: Donna Walker Duggins, John-Paul Mua, Darrell Eugene Holton, Jr., Daniel Verdin Cantrell
-
Patent number: 9629832Abstract: A nicotine-containing particulate material for release of nicotine, the material comprising a combination of nicotine or a pharmaceutically acceptable salt, complex or solvate thereof and a microcrystalline cellulose, The particulate material is stable upon storage and releases nicotine relatively fast. The particulate material can be used in the manufacture of nicotine-containing pharmaceutical composition, wherein the release of nicotine can be designed to be relatively fast so as to obtain a fast onset of action.Type: GrantFiled: April 28, 2014Date of Patent: April 25, 2017Assignee: Niconovum USA, Inc.Inventors: Henri Hansson, Arne Kristensen
-
Patent number: 9402809Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.Type: GrantFiled: March 16, 2007Date of Patent: August 2, 2016Assignee: Niconovum USA, Inc.Inventors: Anders Axelsson, Arne Kristensen, Henri Hansson
-
Publication number: 20140255452Abstract: A nicotine-containing pharmaceutical product configured for insertion into the mouth of a user of that product is provided. The product can have an outer water-permeable pouch, a nicotine-containing pharmaceutical composition situated within the outer water-permeable pouch, and product identifying information relating to the nicotine-containing pharmaceutical composition. The information can be presented such that a user of the product can discern the identifying information by visually inspecting the product and thereby differentiate or identify certain nicotine-containing pharmaceutical products. The product identifying can be, for example, printed, imprinted or dyed on the outer water-permeable pouch, positioned within the outer water-permeable pouch, or attached to the outer water-permeable pouch.Type: ApplicationFiled: March 11, 2013Publication date: September 11, 2014Applicant: NICONOVUM USA, INC.Inventors: Edwin Matthew Reddick, Stephen Taylor Armstrong
-
Patent number: D785277Type: GrantFiled: February 18, 2016Date of Patent: May 2, 2017Assignee: Niconovum USA, Inc.Inventors: E. Matthew Reddick, Travis Swede